The process for evaluating chemical safety is inefficient, costly, and animal intensive. There is growing consensus that the current process of safety testing needs to be significantly altered to improve efficiency and reduce the number of untested chemicals. In this study, the use of short-term gene expression profiles was evaluated for predicting the increased incidence of mouse lung tumors. Animals were exposed to a total of 26 diverse chemicals with matched vehicle controls over a period of 3 years. Upon completion, significant batch-related effects were observed. Adjustment for batch effects significantly improved the ability to predict increased lung tumor incidence. For the best statistical model, the estimated predictive accuracy under honest fivefold cross-validation was 79.3% with a sensitivity and specificity of 71.4 and 86.3%, respectively. A learning curve analysis demonstrated that gains in model performance reached a plateau at 25 chemicals, indicating that the size of current data set was sufficient to provide a robust classifier. The classification results showed that a small subset of chemicals contributed disproportionately to the misclassification rate. For these chemicals, the misclassification was more closely associated with genotoxicity status than with efficacy in the original bioassay. Statistical models were also used to predict dose-response increases in tumor incidence for methylene chloride and naphthalene. The average posterior probabilities for the top models matched the results from the bioassay for methylene chloride. For naphthalene, the average posterior probabilities for the top models overpredicted the tumor response, but the variability in predictions was significantly higher. The study provides both a set of gene expression biomarkers for predicting chemically induced mouse lung tumors and a broad assessment of important experimental and analysis criteria for developing microarray-based predictors of safetyrelated end points.
The general process for evaluating environmental and industrial chemicals for potential human health effects has not changed significantly over the past 30 years. Most of the tests are inefficient and costly and rely heavily on the use of experimental animals. Due to the resource intensive nature of these tests and the current regulations governing product registration, the majority of the chemicals currently in commerce have undergone only limited or no safety testing (Brown, 2003) . Many of these untested chemicals have been sold for more than 20 years (Black, 2008) .
Due to concern over the potential human health effects of these untested chemicals, there are calls for a broad-based effort to significantly overhaul the existing system for testing and regulating environmental and industrial chemicals. In Europe, the registration, evaluation, and authorization of chemicals (REACH) initiative began a phased implementation in 2007 that will substantially alter the safety testing performed on both new and existing chemicals. In the United States, the National Research Council (NRC) recently released a report advocating a fundamental change in the way chemicals are tested (NRC, 2007) . Research efforts by the U.S. Environmental Protection Agency and the National Toxicology Program (NTP) have set out to develop alternative testing programs to prioritize limited testing resources toward chemicals that likely represent the greatest hazard to human health and the environment (Dix et al., 2007; Xia et al., 2008) .
The new efforts in the United States and Europe are not without significant financial and animal costs. By some estimates, the regulations under REACH will directly cost the chemical industry $4.2 billion (Brown, 2003) and require the use of more than 45 million animals over the next 15 years (Breithaupt, 2006; Hofer et al., 2004) . The report by the NRC estimated that many years and hundreds of millions of dollars would be required to perform the research necessary to transform existing toxicology testing (NRC, 2007) . In both cases, the development of more efficient alternatives to the traditional animal tests was listed as one of the primary challenges.
To evaluate the feasibility to develop more efficient and shorter-term alternatives to the standard animal tests, we examined whether gene expression changes following a 13-week exposure to a chemical could accurately predict increased tumor incidence in a standard 2-year rodent cancer bioassay. Chemicals previously tested by the NTP were primarily used to perform the evaluation, and the development of lung tumors in female B6C3F1 mice was used as the end point. Microarray analysis was performed on the lungs of the animals, and the results were analyzed using a broad array of statistical classification and feature selection methods to identify the most robust model. The results provide both a set of gene expression biomarkers that can be immediately applied to predict chemically induced lung tumors in the mouse and a broad assessment of important experimental and analysis criteria for developing microarray-based predictors of safetyrelated end points.
MATERIALS AND METHODS
Chemicals. 1,5-Naphthalenediamine (NAPD, CAS no. 2243-62-1, purity 97%), 2,3-benzofuran (BFUR, CAS no. 271-89-6, purity 99%), N-(1-naphthyl)ethylenediamine dihydrochloride (NEDD, CAS no. 1465-25-4 , purity 98%), pentachloronitrobenzene (PCNB, , purity 99%), 2,2-bis(bromomethyl)-1,3-propanediol (BBMP, CAS no. 3296-90-0, purity 98%), 1,2-dibromoethane (DBET, CAS no. 106-93-4, purity 99%), coumarin (COUM, CAS no. 91-64-5, purity 99%), benzene (BENZ, CAS no. 71-43-2, purity 99%), 2-chloromethylpyridine hydrochloride (CMPH, CAS no. 6959-47-3, purity 98%), 1,4-dichlorobenzene (DCBZ, CAS no. 106-46-7, purity 99%), 1,2,3-trichloropropane (TCPN, CAS no. 96-18-4, purity 99%), propylene glycol mono-t-butyl ether (PGBE, CAS no. 57018-52-7, purity 99%), naphthalene (NPTH, , purity 99%), vanadium pentoxide (VANP, CAS no. 1314-62-1, purity 99.6%), methylene chloride (MECL, CAS no. 75-09-2, purity 99.5%), trichlorofluoromethane (TCFM, CAS no. 75-69-4, purity 99%), and iodoform (IODO, CAS no. 75-47-8, purity > 99%) were purchased from Sigma-Aldrich (St Louis, MO). 1-Amino-2,4-dibromoanthraquinone (ADBQ, CAS no. 81-49-2, purity 99%) was purchased from Apin Chemicals (Oxfordshire, UK). Tris(2,3-dibromopropyl)phosphate (TDPP, , purity > 95%) was purchased from Narchem Corporation (Chicago, IL). Tetrafluoroethylene (TFEL, CAS no. 116-14-3) was purchased from E.I. du Pont de Nemours and Company (Wilmington, DE). Tetrafluoroethane (TFEA, CAS no. 811-97-2, purity 99%) was received from Honeywell Corporation (Morristown, NJ). N-methylolacrylamide (MACR, CAS no. 924-42-5, purity 98%) was purchased from Pfaltz & Bauer (Waterbury, CT). 4-Nitroanthranilic acid (NAAC, CAS no. 619-17-0, purity 98.5%), diazinon (DIAZ, CAS no. 333-41-5, purity 98%), and malathion (MALA, CAS no. 121-75-5, purity 95%) were purchased from Advanced Technology and Industry (Hong Kong, China). Ethylene oxide (ETOX, CAS no. 75-21-8) was purchased from Linde Gas (Cleveland, OH).
Analysis of chemical diversity. Molecular descriptors representing the two-dimensional structure of each of the 26 chemical treatments were downloaded from PubChem in the simplified molecular input line entry specification (SMILES) format. SMILES codes for all single chemicals tested in the NTP rodent cancer bioassay were downloaded from DSSTox (Richard et al., 2006) . The SMILES code for each chemical was converted into a chemical fingerprint using the GenerateMD software application (Version 3.1.7.1; JChem, ChemAxon, Budapest, Hungary). The chemical fingerprints were then compared for structural similarity using the Tanimoto coefficient and the Compr software application (Version 3.1.7.1; JChem, ChemAxon).
Animals and treatment. Female B6C3F1 mice were obtained from Charles River Laboratories (Raleigh, NC). Twenty-five of the 26 chemicals used in this study have been previously tested by the NTP, and the results were summarized in Table 1 . The remaining chemical, tetrafluoroethane, was independently tested in a 2-year rodent bioassay (Alexander et al., 1995) . The animal studies were performed in multiple phases across multiple years (Supplementary Table 1 ). With each chemical treatment, a matched vehicle control group was run concurrently with the exposure. A subset of two chemicals, methylene chloride and naphthalene, were performed in a five-point dose response with a matched purified air control group (Table 2) . The concentrations for these exposures overlapped those in the original NTP rodent bioassay.
Animals were exposed for a total of 13 weeks. The rationale for choosing the 13-week time point was threefold. First, the 13-week time point is a standard time for many toxicological studies. As a result, the prediction of carcinogenic activity could be easily integrated into the existing testing paradigm. Second, many nongenotoxic carcinogens cause a transitory increase in cell proliferation followed by a period of negative selection (Andersen et al., 1995) . Therefore, performing these studies following shorter exposures would likely identify gene signatures that would be less robust with a more transient predictive window. Third, the gene expression signatures for predicting carcinogenic activity would naturally evolve over the time course of treatment. At shorter time points, the gene signatures would likely be more chemical or mechanism specific. Over time, the signatures would evolve from mechanismspecific to more uniform signatures, indicative of the transition to a neoplastic state.
Mice were housed in a temperature-controlled (17.8°C-26.1°C) and humidity-controlled (30-70%) environment with a standard 12-h light/dark cycle. Airflow within the housing environment was maintained at 12-15 air changes per hour. The animals were provided access to water purified by reverse osmosis and certified ground NIH-07 food (Zeigler Brothers, Inc., Gardners, PA) ad libitum except for animals exposed via inhalation where food and water were withheld during exposures. At the beginning of each study, the mice were randomized by weight and divided into treatment groups. Animal treatment was initiated at 5-6 weeks of age and were performed via the route and dose listed in Table 1 . For food and gavage exposures, mice were housed five per cage in polycarbonate cages. Gavage exposures were administered 5 days per week, and feed exposures were provided 7 days per week. For inhalation exposures, mice were exposed 6 h per day, 5 days per week, in either 1-m 3 whole-body inhalation chambers (Hazelton H1000; Lab Products, Seaford, DE) or single-animal whole-body chambers (Wong et al., 2008) . For animals exposed in the 1-m 3 whole-body inhalation chambers, they were also housed individually in the chamber during nonexposure periods. For animals exposed in the single-animal whole-body chambers, they were placed into the chambers prior to the start of exposure and then removed from the chambers and returned to domiciliary housing (five animals per cage) at the end of the 6-h exposure.
Animal use in this study was approved by the Institutional Animal Use and Care Committee of CIIT Centers for Health Research and was conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. Animals were housed in fully accredited American Association for Accreditation of Laboratory Animal Care facilities.
Necropsy and histology. Following 13 weeks of exposure, the mice were euthanized with a lethal ip dose of sodium pentobarbital (Abbott Laboratories, Chicago, IL). The four right lung lobes were isolated by suturing, removed, and minced together in RNAlater (Ambion, Austin, TX). The left lung lobe was inflated with 10% neutral buffered formalin. The formalin-fixed lung samples were embedded into paraffin blocks, sectioned at 5 lm, and stained with hematoxylin and eosin. Histological changes were assessed by an accredited pathologist.
Gene expression microarray analysis. Microarray analysis was performed on three to five animals per treatment or concurrent vehicle control group. A total of 191 animals were analyzed for lung gene expression (Supplementary Table 1 ). Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). The isolated RNA was further purified using RNeasy columns (Qiagen, Valencia, CA) , and the integrity of the RNA was verified spectrophotometrically and with the Agilent 2100 Bioanalyzer (Palo Alto, CA) (Supplementary 312 THOMAS ET AL. Table 2 ). Double-stranded complementary DNA (cDNA) was synthesized from 5 lg of total RNA using the One-Cycle cDNA Synthesis Kit (Affymetrix, Santa Clara, CA). Biotin-labeled complementary RNA (cRNA) was transcribed from the cDNA using the GeneChip IVT Labeling Kit (Affymetrix). Fifteen micrograms of labeled cRNA was fragmented and hybridized to Affymetrix Mouse Genome 430 2.0 arrays for 16 h at 45°C. The hybridized arrays were washed using the GeneChip Fluidics Station 450 and scanned using a GeneChip 3000 scanner. The gene expression results have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (accession no. GSE17933) and the Chemical Effects in Biological Systems knowledgebase (accession no. 004-00006-0010-000-1).
Gene expression microarray data normalization and batch effect removal. The expression data were analyzed using the SAS JMP Genomics software (Version 4.0; SAS Institute Inc., Cary, NC). Affymetrix CEL files were imported at the probe level and log 2 transformed, and each probe set was summarized using the mean of the corresponding probes. Each array was normalized by subtracting its overall mean value. A principal components analysis showed significant batch effects when analyzed across the different studies that comprise the 26 different chemical treatments and corresponding vehicle control groups (Fig. 1A) . The batch effects were evident despite different normalization algorithms (e.g., mean standardized, MAS5, RMA, and GCRMA) (data not shown).
To adjust for the batch effects, grouped-batch-profile (GBP) normalization (Chu et al., 2009 ) was applied. GBP normalization estimates the profile of each batch level via the average across within-batch controls, defines groups of genes by k-means clustering on batch profiles, and corrects the batch effect in all genes using the corresponding GBP. Since chemical exposures with the corresponding vehicle controls and microarray hybridizations were performed as a series of four studies over a period of 3 years, we defined a batch according Note. F, feed; GC, gavage, corn oil (5 ml/kg); GW, gavage, deionized water (5 ml/kg); I, inhalation; n/a, not applicable.
a
The results for lung tumors in this study were equivocal with a statistically significant increase in alveolar/bronchiolar adenomas (p ¼ 0.048) but not with a significant increase in the combined alveolar/bronchiolar adenomas or carcinomas ( p ¼ 0.222). In the classification analysis in this study, TCPN was assumed to be tumorigenic.
to vehicles within study ID, resulting in a total of 14 batches for the analysis. For k-means clustering, after comparing the results of different cluster numbers (50, 100, 200, 500, and 1000), 500 was selected as the number to use for the final normalization. GBP batch normalization removed the majority of the batch effects observed in the data (Fig. 1B) . The batch-normalized data were further summarized by averaging probe set responses for all animals receiving the same chemical treatment. This was done because we wished to perform standard prediction and cross-validation at the chemical level but not at the animal level.
Statistical classification analysis. Statistical classification analysis was performed using a suite of 84 different models and feature selection algorithms in JMP Genomics software (Version 4.0; SAS Institute Inc.). The 84 models included 8 discriminant analysis, 8 distance scoring, 12 general linear, 8 k-nearest neighbor, 13 logistic regression, 15 partial least squares, 16 partition tree, and 4 radial basis machine models. Detailed descriptions and parameters for each model are provided in Supplementary Tables 4-12. The predicted end point was increased lung tumor incidence in female B6C3F1 mice according to the rodent cancer bioassay (Table 1) . To assess the predictive accuracy of the classification models on the current data sets, a range of cross-validation conditions were performed including leave-one-out, twofold random partition (10 iterations), fivefold random partition (10 iterations), fivefold random partition (20 iterations), and 10-fold random partition (10 iterations). The comparison of the different cross-validation conditions is shown in Supplementary Figure 1 . For most of the subsequent results, fivefold cross-validation using random partition (10 iterations) was used.
RESULTS

Structural Diversity among Chemical Treatments
The 26 chemical treatments in the study were intentionally chosen to be diverse in terms of chemical structure, genotoxicity, and potential modes of action. The structural diversity among the chemicals was analyzed using a Tanimoto similarity coefficient, with a coefficient of 1.0 being identical molecules and 0.0 having no structural similarity. The average similarity among all 26 chemicals in the study was 0.143 (range 0.000-0.688). By comparison, the average similarity for all single chemicals tested by the NTP in a rodent cancer bioassay was 0.155 (Thomas et al., 2007) .
Histological Changes
Gross histological examination of the lung tissue identified treatment-related lesions in NAPD-, TCPN-, VANP-, and NPTH-treated animals. In the NAPD treatment group, morphological changes were found in all five animals examined and were limited to the bronchiolar epithelial cells, which exhibited karyomegaly and karyorrhexis. There was occasional peribronchiolar infiltration by neutrophils and mononuclear cells. Bronchiolar epithelial cell morphology was suggestive of regenerative hyperplasia. In the TCPNtreated group, bronchiole degeneration was observed in eight of the nine animals examined. The degeneration was in the terminal bronchioles and consisted of large or irregular nuclei, 
FIG. 1.
Principal components analysis of the gene expression data before (A) and after (B) adjusting for batch effects. The colors represent the different years that the study was run (red, 2005; green, 2006; and blue, 2007) , and individual animals are represented by the symbols. All probe sets on the array were used in the analysis.
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THOMAS ET AL. pyknosis, and eosinophilic cytoplasm, with occasional flattening of the epithelium. In the VANP-treated animals, alveolar epithelial hyperplasia, inflammation, and degeneration of the bronchiolar epithelium were observed in all 10 animals examined. In the NPTH treatment group, mild bronchiole epithelial degeneration was observed in all 10 of the animals examined. In general, histological changes alone in the lung were not predictive of increased tumor incidence in a 2-year bioassay. This result is consistent with a previous study that reported the poor predictive properties of histological lesions (Allen et al., 2004) .
Impact of Batch Effects on Classification Performance and Treatment-Related Variance
In addition to the standard quality control metrics for Affymetrix microarrays, batch-related effects were examined using principal components and variance components analysis. The batch effects associated with the study over its 3-year period were significant (Fig. 1 ) and could be attributed to both technical and biological variabilities. To adjust for these effects, the matched vehicle control groups were first used to estimate batch-related profiles. The batch profiles were then subtracted from associated treatment groups, reducing the relative proportion of variation associated with batch effects from 57 to 10% (Fig. 2) and eliminating the grouping of samples based on study year (Fig. 1) . The impact of the batch effects on classification performance was considerable. In the unadjusted data, the average classification accuracy, area under the receiver operator characteristics curve (AUC), and root mean square error (RMSE) across the 84 models were 0.554, 0.536, and 0.591, respectively (Fig. 3) . For batch-adjusted data, all metrics associated with classification performance were increased. The average classification accuracy, AUC, and RMSE following batch adjustment were 0.677, 0.698, and 0.504, respectively. A complete list of performance metrics for all the models is provided in Supplementary Table 3. The adjustment for batch effects improved the amount of variance attributed to both treatment-specific effects and the tumorigenicity status of the treatment itself (Fig. 2) . The variance attributed to chemical treatment increased from 6.7 to 22.8%, while the amount attributed to the tumorigenicity status increased from 1 to 2.2%. Although the amount of variance attributed to the tumorigenicity status of the treatment more than doubled, the relative proportion of the total variance related to tumorigenicity was limited. Biologically, these results suggest that within the gene expression profile of a particular chemical treatment, the amount of information that is capable of distinguishing whether it is tumorigenic or not is relatively small, while other treatment-specific effects, unrelated to the tumorigenic activity, predominate.
Statistical Classification Analysis to Predict Increased Lung Tumor Incidence
To understand the potential impact of the specific algorithms used for statistical classification, a broad selection of statistical classification models and feature selection algorithms were tested. The results showed that certain methods, such as logistic regression, partial least squares, and radial basis machines, performed better on average across multiple measures of performance (Fig. 4) . However, four of the five top performing models used discriminant analysis and general linear models as the classifiers. Although these methods produced some of the most accurate classifiers, discriminant analysis and general linear models showed larger ranges in classification performance than did other methods, suggesting that the performance of these methods are more sensitive to the range of selected tuning parameters (including feature selection methods) they were paired with and perhaps also a greater tendency to overfit the data.
The overall predictive power of the experimental approach was assessed by examining the top five performing classification models in greater detail. Among the best five models, the average accuracy was 77.5%, with an average sensitivity and specificity of 71.3 and 83%, respectively. The top performing model used an initial t-test screen for feature selection and stepwise discriminant analysis for classification. The predictive accuracy for the top model was estimated at 79.3 with 95% confidence intervals spanning 70 to 86.5% (Fig. 5) . These results were achieved using honest fivefold cross-validation, with feature selection and model fitting conducted anew on each training set. Results with 10-fold cross-validation were similar while leave-one-chemical-out cross-validation results resulted in a higher accuracy estimate of nearly 90%. The cross-validation results suggest that fivefold cross-validation is moderately conservative and should provide reasonable estimates of the accuracy of the model when applied to external data sets.
Among the 84 models analyzed, specificity was generally higher than sensitivity, suggesting that detecting true positives was more difficult than detecting true negatives Supplementary Fig. 2 ). The balance between sensitivity and specificity is particularly important for hazard identification in a regulatory environment. For regulatory applications, any reduction of false negatives would be desirable even at the expense of increased false positives. Therefore, choosing the model with the highest sensitivity may be necessary as opposed to the most accurate model. The highest sensitivity (74.3%) was achieved using stepwise discriminant analysis, with t-test for feature selection (Supplementary Table 3 ). The specificity and accuracy of this model was 83.1 and 79%, respectively.
Analysis of Learning Curves to Identify the Minimal Training Set Size
To evaluate whether the size of the current training set of chemicals was sufficient for accurately predicting a tumorigenic response, a learning curve analysis was performed. In this analysis, random samples of chemical treatments were selected from the total pool of 30 treatments. For each random sample of treatments, the statistical classification analysis and crossvalidation were performed. The size of the random sample (i.e., size of the training set) was incrementally increased to evaluate the change in performance. The best performing model from each classification method was used in the analysis. For most of the classification methods, the predictive accuracy reached a plateau at~25 treatments (Fig. 6 ). For the two classification methods that did not reach a plateau, the radial basis machine and discriminant analysis models, the gain in accuracy after 25 treatments was minimal. Similar results were observed for AUC and RMSE. These results suggest that the size of current data set was appropriate to provide a reasonably robust classifier for predicting mouse lung tumors using gene expression data. Assuming that the diversity of the current chemical set is sufficient, adding additional treatments would have minimal impact on the overall accuracy of the final model.
Chemical Differences in Misclassification Rate
Among the chemical treatments analyzed, BBMP was the most challenging to classify. When analyzed across the crossvalidation runs of all 84 classification models, BBMP was correctly classified 0.7% of the time (Fig. 7, top) . No improvement was observed when analyzed with the top 10 performing models (Fig. 7, bottom) . Based on the top 10 performing models, other challenging chemicals included PGBE, MALA, NAAC, NPTH, and TDPP. To understand potential factors contributing to the difficulty in classifying these chemicals, associations between the rate of misclassification and factors such as tumor incidence in the bioassay and genotoxicity status were evaluated. For both the tumorigenic and the nontumorigenic chemicals, the correlation between the correct classification rate and the tumor incidence in the original bioassay was not significant (tumorigenic: r ¼ 0.171, p > 0.1; nontumorigenic: r ¼ 0.249, p > 0.1), while the ability to correctly classify nontumorigenic chemicals showed a slightly higher correlation (r ¼ 0.249, p > 0.1). This suggests that the chemicals with the highest tumor incidence are not necessarily the most easy to classify based on gene expression. Further analysis based on the Ames test results showed that three of the four frequently misclassified tumorigenic chemicals (NPTH, TDPP, and MACR) were negative in the Ames test, while the two frequently misclassified nontumorigenic chemicals were positive. These results suggest that nongenotoxic lung tumorigens are more difficult to correctly classify and are more likely to lead to false negatives when the tumorigenic activity is predicted based on gene expression data. Conversely, genotoxic nontumorigens are more likely to lead to false positives.
Predicting Dose-Response Behavior of Chemical Carcinogens
To assess the ability to predict increased tumor incidence as a function of dose, animals were exposed by inhalation in a five-point concentration response to two chemicals that produced significant increases in lung tumors (MECL and NPTH). The exposure concentrations overlapped those in the original rodent cancer bioassay. Gene expression microarray analysis was performed on the lungs, and the statistical classification models were then used to predict increased lung tumor incidence. For MECL, the average posterior probabilities for 2000, 3000, and 4000 ppm concentrations were all above the 0.5 decision point, leading to a predicted increase in lung tumors (Fig. 8) . The 100 and 500 ppm concentrations were below the 0.5 posterior probability threshold and not predicted to be tumorigenic. For the top five models, the variability in the posterior probability estimates was minimal and did not span the 0.5 posterior probability threshold except for the 3000 ppm concentration. The statistical predictions for the higher concentrations matched the results in the original cancer bioassay where a significant increase in lung tumors was seen at 2000 and 4000 ppm (NTP, 1986) . No lower concentrations were tested in the bioassay, prohibiting the evaluation of the statistical predictions at the 100 and 500 ppm concentrations.
For NPTH, a clear dose-response behavior was observed in the average posterior probability, but no concentrations were below the 0.5 posterior probability decision point (Fig. 8) . The predictions by the statistical models at the lower concentrations were not consistent with the results in the original bioassay. A significant increase in lung tumors by NPTH was seen at 30 ppm, while no increase in tumors was observed at 10 ppm (NTP, 1992) . However, the variability in the posterior probabilities at the three lowest doses was significant, providing considerable uncertainty in the confidence of the predictions.
DISCUSSION
Due to a series of highly publicized recommendations by expert panels and changing regulatory requirements in Europe and the United States, there is a growing sentiment that the process of evaluating the safety of environmental and industrial chemicals needs to be improved. How this process is redefined and what models are used to evaluate chemical safety are still under debate; however, in most cases, transcriptomic technologies are likely to play a key role in any testing paradigm. In this study, the use of short-term gene expression profiles for predicting the increased incidence of mouse lung tumors was evaluated. Experimentally, female B6C3F1 mice were exposed for a period of 13 weeks to a selection of 26 chemicals, of which approximately half produced an increased incidence of lung tumors in a 2-year rodent cancer bioassay. The chemicals were intentionally chosen to be diverse in terms of chemical structure, route of exposure, and genotoxicity in order to reflect, as much as possible, the broad assortment of environmental and industrial chemicals that currently exist. The 13-week duration of exposure was chosen in order to provide a relatively stable molecular profile that would reflect a potential transition to a tumorigenic state. Microarray analysis was performed on the lungs of the animals, and the results were analyzed using a broad array of statistical classification and feature selection methods to identify the most robust model.
In a study of this size, the chemical exposures and subsequent microarray analysis were performed over a period of several years, leading to significant batch-related variability. These batch effects are not uncommon in large microarray studies , but few studies exist on the extent of their impact on analysis results. This is particularly true for the impact of batch effects on classification performance in the use of microarrays for predicting health-related outcomes. In the current study, matched vehicle control groups were run with each chemical treatment and used to adjust for batch-related variability. From the variance components analysis, the adjustment for batch effects also improved the amount of variance attributed to both treatment-specific effects and the tumorigenicity status of the treatment. The adjustment for batch effects also resulted in a significant improvement in both standard quality metrics of the microarray data and the predictive performance of the statistical models. On average, the adjustment for batch effects improved the accuracy of the various statistical classification models.
Based on the top performing classification models, the average accuracy using the gene expression changes to predict increased lung tumor incidence was 77.5%. By comparison, previous studies using gene expression changes to predict nongenotoxic rat liver tumors obtained accuracies ranging from 82 to 84% (Fielden et al., 2007; Nie et al., 2006) . The predictive accuracies of the rat liver studies were subsequently reduced upon further validation to 55-69% (Fielden et al., 2008) . The results from the present study are slightly higher than those in the rat study, but they are within the 95% confidence bounds of the top three performing models. Given the similarities in the predictive accuracies of these studies across different tissues and species, the results suggest that the FIG. 6 . Learning curve analysis. Random samples were selected from the total pool of 30 treatments. For each random sample of treatments, the statistical classification analysis and cross-validation were performed. The size of the random sample (i.e., size of the training set) was incrementally increased to evaluate the change in accuracy, AUC, and RMSE. The best performing model from each classification method was used in the learning curve analysis.
generalized application of transcriptomic technologies can achieve between 60 and 80% accuracy when predicting longterm safety-related end point when based on expression changes following short-term exposures.
In applying the statistical classification models to predict the dose-response increases in tumor incidence, two chemicals that were positive for lung tumors in the rodent bioassay were evaluated in a five-point concentration response. For MECL, the statistical classification predictions closely matched the results from the bioassay, while for NPTH, the average posterior probabilities overpredicted the tumorigenic response. However, there was considerable variability in the posterior probability estimates, allowing little confidence in the predictions. The variability in the predictions suggests that the gene expression changes in the signatures for the top statistical models were conflicting and not providing a clear decision boundary for the tumor prediction. The reason for the conflicting gene expression changes was not clear; however, significant lung pathology was observed at the lower dose in bioassay despite the lack of tumors (NTP, 1992) . For both chemicals, clear dose-response behavior was observed in the posterior probabilities of the statistical classification models. Although it is difficult to draw firm conclusions from only two chemicals, the results suggest that the dose-response behavior in tumorigenic activity is reflected in the posterior probability of the classification models, but a binary prediction of increased tumor incidence may be an oversimplification for certain chemicals.
To the extent that the results from this study can be generalized to other organs and species, several important experimental design and analysis guidelines emerged from the investigation. First, adjusting for batch-related variability significantly increased the predictive performance of virtually all the statistical classification models. These batch-related effects are common in microarray studies, and if transcriptomic technologies are going to be broadly applied in toxicology testing, standardized methods for batch adjustment will be necessary for optimum performance. Second, the learning rate analysis provided important insights into the FIG. 8. Dose-response prediction of increased lung tumor incidence for methylene chloride (MECL) and naphthalene (NPTH). Animals were exposed by inhalation in a five-point concentration response. The exposure concentrations overlapped those in the original rodent cancer bioassay. Gene expression microarray analysis was performed on the lungs, and the statistical classification models were then used to predict increased lung tumor incidence. The data points represent the mean and SDs of the posterior probabilities of the top five statistical classification models.
FIG. 7.
Breakdown of the classification results by treatment group. The correct classification rate was calculated based on the number of times the chemical was correctly classified over all the cross-validation runs (fivefold cross-validation, random partition, and 10 iterations). The results were summed over all 84 classification models (top) or the top 10 classification models (bottom). The red symbols denote treatments positive for lung tumors, and blue symbols are negative treatments.
PREDICTING CHEMICALLY INDUCED LUNG TUMORS 319 experimental design of future microarray studies, attempting to identify predictive biomarkers. For these studies, a minimum of 25 diverse chemicals will be required to develop a robust predictive model. In selecting these chemicals, a predisposition toward selecting the most tumorigenic and nongenotoxic chemicals will not provide the most robust overall model. There was no correlation between the rate of misclassification and tumor incidence in the original bioassay, and selecting only nongenotoxic chemicals will add significant bias to the final model since it will increase false negatives and decrease false positives. Finally, the analysis of the data using a broad array of statistical classification and feature selection methods provided guidance on which methods demonstrated the best overall performance. Although certain methods tended to provide the most predictive models, these methods were also the most variable in their performance. Additional research will be needed to understand the impact of this variability.
These guidelines can be applied to identify a battery of gene expression biomarkers that are capable of broadly predicting long-term cancer hazard following a short-term exposure. Based on NTP records, developing gene expression biomarkers for a combination of eight organs from rats and mice of specific sexes would identify nearly 80% of all positive chemicals in the rodent cancer bioassay. Therefore, conservatively assuming no overlap among chemicals across multiple organs, a predictive battery of gene expression biomarkers could be developed for these eight tissues using only 200 chemical exposures (8 3 25). The chemicals chosen should be diverse in terms of structure and include both genotoxic and nongenotoxic modes of action. To reduce batch-related effects, the samples for the microarray analysis should be randomized and run in as short a time frame as possible. For large-scale prioritization and regulatory efforts, such as ToxCast in the United States and REACH in Europe, the development of these biomarkers would provide a relatively efficient and costeffective method for identifying chemicals of concern.
In summary, the results from these studies provide both a set of gene expression biomarkers that can be immediately applied to predict chemically induced lung tumors in the mouse and a broader evaluation of the use of transcriptomic technologies to predict the long-term safety of environmental and industrial chemicals. Given that transcriptomic studies are likely to play a significant role in the reshaping of toxicology and chemical testing, a comprehensive analysis of key factors that determine the success of these studies will provide insights into the design of future studies and how they can best be integrated into a larger testing paradigm.
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